ScienceLife Sciences

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Play

Open in

81 episodes
Avg 5 min
English

Episodes 81

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Monday · 2 min
Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb
Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.
Monday · 37 min
The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
Friday · 2 min
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.
Friday · 37 min
Building Biopharma Manufacturing for Speed, Scale, and Flexibility
Biopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more readily to changing development timelines and demand forecasts — all while maintaining reliable, compliant, and cost-effective supply. In this episode of the Pharm Exec Podcast, Dave Maraldo, Ph.D., executive vice president and president of the Merck Manufacturing Division, draws on 27 years at the company to explore that evolution. He discusses Merck’s major U.S. capacity investments; its approach to balancing internal capabilities with strategic manufacturing partners; and the closer integration of research, development, and production. Joining Mike Christel, group managing editor, MJH Life Sciences, Maraldo also examines the practical impact of digital tools and artificial intelligence and how Merck is building greater agility and resilience into its global supply network. He reflects ahead as well on what the next generation of manufacturing talent will require and why he thinks patient needs will move closer and closer to the shop floor.
October 22 · 2 min
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
October 21 · 2 min
Pharmaceutical Executive Daily: FDA Approves Hibsago
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
October 20 · 2 min
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli
METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.
October 19 · 2 min
Pharmaceutical Executive Daily: Hansoh Pharma Enters Collaboration and License Agreement with Roche for Broad Portfolio of ADCs
Merck KGaA, Darmstadt, Germany, acquires Silence Therapeutics for $1.3 billion, Hansoh Pharma and Roche expand their ADC partnership in a deal worth over $15 billion, and an EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe.
October 14 · 2 min
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
October 13 · 2 min
Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
October 12 · 2 min
Pharmaceutical Executive Daily: Thomas Appio Named Interim CEO of Bausch + Lomb
Bausch + Lomb names Thomas Appio interim CEO as Brent Saunders departs, a Pharm Exec interview explores how AI is reshaping entry-level apprenticeship in professional services, and a LogiPharma 2026 conversation makes the case against waiting for perfect data to deploy AI in pharma supply chains.
October 9 · 2 min
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
October 8 · 2 min
Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
October 7 · 2 min
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
October 6 · 3 min
Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.
October 6 · 27 min
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
Can artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Pharm Exec podcast, Matt Walz, CEO of Trialbee, a patient recruitment company, joins Mike Christel, group managing editor, MJH Life Sciences, to discuss how AI is enhancing medical screening, clinical workflows, and enrollment planning. The conversation explores the need for clearer regulatory expectations, human oversight, and workforce training — and why predicting enrollment costs and timelines, Walz believes, could offer one of AI’s most consequential opportunities in clinical trials. Walz also shares how Trialbee is deploying AI on both the patient-facing and operational sides of its business and explains how conversational tools are helping teams move from the world of dashboards to more specific answers.
October 5 · 3 min
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.
October 2 · 3 min
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.
October 1 · 2 min
Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
September 30 · 2 min
Pharmaceutical Executive Daily: Peptide Ruling Stalls
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.

Showing 1–20 of 81 episodes